Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 104

The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.

Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

Stine, Jonathan G., Lewis, James H.·2016·Expert Review of Gastroenterology & Hepatology
DOI 10.1586/17474124.2016.1127756PMC PMC5074808
Open this paper in CoChat — free account

Abstract

While the pace of discovery of new agents, mechanisms and risk factors involved in drug-induced liver injury (DILI) remains brisk, advances in the treatment of acute DILI seems slow by comparison. In general, the key to treating suspected DILI is to stop using the drug prior to developing irreversible liver failure. However, predicting when to stop is an inexact science, and commonly used ALT monitoring is an ineffective strategy outside of clinical trials. The only specific antidote for acute DILI remains N-acetylcysteine (NAC) for acetaminophen poisoning, although NAC is proving to be beneficial in some cases of non-acetaminophen DILI in adults. Corticosteroids can be effective for DILI associated with autoimmune or systemic hypersensitivity features. Ursodeoxycholic acid, silymarin and glycyrrhizin have been used to treat DILI for decades, but success remains anecdotal. Bile acid washout regimens using cholestyramine appear to be more evidenced based, in particular for leflunomide toxicity. For drug-induced acute liver failure, the use of liver support systems is still investigational in the United States and emergency liver transplant remains limited by its availability. Primary prevention appears to be the key to avoiding DILI and the need for acute treatment. Pharmacogenomics, including human leukocyte antigen genotyping and the discovery of specific DILI biomarkers offers significant promise for the future. This article describes and summarizes the numerous and diverse treatment and prevention modalities that are currently available to manage DILI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/17474124.2016.1127756

Cites

192 of 192 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 20

  1. Saliba F, 2015, Minerva Med, 106, 35
  2. Lewis JH, 2012, Gastroenterol Hepatol, 8, 333
  3. Thongraung W, 2012, Southeast Asian J Trop Med Public Health, 43, 724
  4. Chan ST, 2015, Hong Kong Med J, 21, 389
  5. Ahmed T, 2015, BMJ Case Rep
  6. Lee WM, 1989, J S C Med Assoc, 85, 75
  7. Bessone F, 2015, Liver Int
  8. Prandota J, 2005, Am J Ther, 12, 254
  9. O’Brien CB, 1996, Am J Gastroenterol, 91, 1456
  10. Mork H, 1997, Z Gastroenterol, 35, 1087
  11. Gu J, 2015, Int J Clin Exp Med, 8, 4320
  12. Wang GS, 1993, Yao Xue Xue Bao, 28, 572
  13. Xiong H, 2012, Zhonghua Er Ke Za Zhi Chin J Pediatr, 50, 890
  14. Neuvonen PJ, 1985, Int J Clin Pharmacol Ther Toxicol, 23, 497
  15. Poirier LA, 1986, Adv Exp Med Biol, 206, 269
  16. Matsumoto K, 2015, J Chemother (Florence, Italy), 1973947815
  17. Civan JM, 2014, Gastroenterol Hepatol, 10, 27
  18. Blanchette CM, 2015, Drugs Context, 4
  19. Lee SW, 2010, Int J Tuberc Lung Dis, 14, 622
  20. Isoda K, 2011, Pharmazie, 66, 278

Cited by

See all 104

Metadata

Authors
Stine, J. G., & Lewis, J. H.
Venue
Expert Review of Gastroenterology & Hepatology
Publisher
Informa UK Limited
Published
2015-12-25
Volume
10
Issue
4
Pages
517-536
ISSN
  • 1747-4124
  • 1747-4132
DOI
10.1586/17474124.2016.1127756
PMC
PMC5074808
Cited by
104
References
192
Language
en
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007769)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.